← Praxis Precision Medicines, Inc. (PRAX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Praxis Precision Medicines, Inc. (PRAX)
Pharmaceutical Preparations · market cap $8.0B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
11
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Praxis Precision Medicines (PRAX) is a clinical-stage pharmaceutical company with a $9.1B market cap and 116 employees, focused on precision CNS therapies spanning epileptic encephalopathies, essential tremor, focal epilepsy, and major depressive disorder. The company carries no revenue, $536M in cash (runway ~18.7 months), and is burning roughly $267M annually in R&D. Its most immediate binary is a Phase 3 readout for PRAX-562 in SCN2A-related Developmental and Epileptic Encephalopathy (DEE) expected around July 15, 2026, with a second readout from the same program expected in December 2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · 1.0mg/kg/day PRAX-562imp 9/10
- 2027-01-15 (est.)Phase 3 · 40 mg/day vormatrogine for 12 weeksimp 9/10
- 2027-01-31PDUFAimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Part A: 20 and 40 mg PRAX-944 | Phase 2 | Essential Tremor |
| PRAX-562 | Phase 3 | SCN2A Encephalopathy |
| 10 mg PRAX-114 | Phase 2 | Major Depressive Disorder |
| 100 mg PRAX-944 | Phase 2 | Essential Tremor |
| 1mg elsunersen | Phase 3 | Epileptic Encephalopathy |
| 1.0mg/kg/day PRAX-562 | Phase 3 | Developmental and Epileptic Encephalopathy 1 |
| 40 mg/day vormatrogine for 12 weeks | Phase 3 | Focal Epilepsy |
| 30mg PRAX-628 | Phase 2 | Focal Onset Seizure |
| 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks | Phase 3 | Focal Seizure |
| PRAX-114 | Phase 3 | Major Depressive Disorder |
| PRAX-222 - Initial Dose | Phase 2 | SCN2A-DEE |
Price & technical context
3-month
-9.9%
6-month
-10.1%
12-month
+441.3%
52-wk range
$50.98–$386.33
vs 50-day MA
-14.0%
vs 200-day MA
-9.4%
Realized vol
128.0%
Max drawdown
-68.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PRAX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.